Elite in Chronic Myelogenous Leukemia (CML)

Dr. Michael C. Heinrich

University Professional Services
Portland, OR
Elite
in Chronic Myelogenous Leukemia (CML)
Specialties:Hematology Oncology | Hematology | Oncology
Accepting New Patients
Offers Telehealth
OverviewInsuranceLocationsClinical Research

Overview

Michael Heinrich is a Hematologist Oncology specialist and a Hematologist in Portland, Oregon. Dr. Heinrich and is rated as an Elite provider by MediFind in the treatment of Chronic Myelogenous Leukemia (CML). His top areas of expertise are Gastrointestinal Stromal Tumor, Chronic Myelogenous Leukemia (CML), Undifferentiated Pleomorphic Sarcoma, and Mesenchymoma. Dr. Heinrich is currently accepting new patients.

His clinical research consists of co-authoring 131 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 6 articles and participated in 5 clinical trials in the study of Chronic Myelogenous Leukemia (CML).

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in OR
Hospital Affiliations
Ohsu Hospital And Clinics
Languages Spoken
English
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  BridgeSpan
  •  PacificSource
  •  Regence
  •  Humana

Locations

UNIVERSITY PROFESSIONAL SERVICES
3303 S Bond Ave, Portland, OR 97239
503-494-8311
Other Locations
UNIVERSITY PROFESSIONAL SERVICES
3181 Sw Sam Jackson Park Rd, Portland, OR 97239
503-494-8311
UNIVERSITY PROFESSIONAL SERVICES
15700 Sw Greystone Ct, Beaverton, OR 97006
503-494-3442

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients With Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses
A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients With Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses
Enrollment Status: Active_not_recruiting
Publish Date: January 08, 2025
Intervention Type: Drug
Study Drug: Ponatinib
Study Phase: Phase 2
A Phase 3, Multi-center, Open-label, Randomized Study of Oral ABL001 Versus Bosutinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase (CML-CP), Previously Treated With 2 or More Tyrosine Kinase Inhibitors
A Phase 3, Multi-center, Open-label, Randomized Study of Oral ABL001 Versus Bosutinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase (CML-CP), Previously Treated With 2 or More Tyrosine Kinase Inhibitors
Enrollment Status: Active_not_recruiting
Publish Date: December 27, 2024
Intervention Type: Drug
Study Drugs: ABL001, Bosutinib
Study Phase: Phase 3
An Open-Label, Phase 2 Efficacy Study of Temozolomide (TMZ) in Advanced Succinate Dehydrogenase (SDH)-Mutant/Deficient Gastrointestinal Stromal Tumor (GIST)
An Open-Label, Phase 2 Efficacy Study of Temozolomide (TMZ) in Advanced Succinate Dehydrogenase (SDH)-Mutant/Deficient Gastrointestinal Stromal Tumor (GIST)
Enrollment Status: Active_not_recruiting
Publish Date: November 04, 2024
Intervention Type: Drug
Study Drug: Temozolomide
Study Phase: Phase 2
A Randomized Phase II Study of Ruxolitinib (NSC-752295) in Combination With BCR-ABL Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia (CML) Patients With Molecular Evidence of Disease
A Randomized Phase II Study of Ruxolitinib (NSC-752295) in Combination With BCR-ABL Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia (CML) Patients With Molecular Evidence of Disease
Enrollment Status: Active_not_recruiting
Publish Date: July 08, 2024
Intervention Type: Drug, Other
Study Drugs: Bosutinib, Dasatinib, Nilotinib, Nilotinib Hydrochloride Monohydrate, Ruxolitinib, Ruxolitinib Phosphate
Study Phase: Phase 2
A Phase I, Multicenter, Open-label Study of Oral ABL001 in Patients With Chronic Myelogenous Leukemia (CML) or Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL)
A Phase I, Multicenter, Open-label Study of Oral ABL001 in Patients With Chronic Myelogenous Leukemia (CML) or Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL)
Enrollment Status: Completed
Publish Date: March 18, 2024
Intervention Type: Drug
Study Drugs: ABL-001, Dasatinib, Nilotinib, Imatinib
Study Phase: Phase 1
An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)
An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)
Enrollment Status: Completed
Publish Date: October 06, 2022
Intervention Type: Drug
Study Drugs: Avapritinib, Regorafenib
Study Phase: Phase 3
A Phase 1, Open-label, Dose-escalation and Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CDX-0158 in Adult Patients With KIT Positive Advanced Solid Tumors.
A Phase 1, Open-label, Dose-escalation and Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CDX-0158 in Adult Patients With KIT Positive Advanced Solid Tumors.
Enrollment Status: Completed
Publish Date: June 12, 2019
Intervention Type: Biological
Study Phase: Phase 1
View 6 Less Clinical Trials

131 Total Publications

The INSIGHT study: a randomized, Phase III study of ripretinib versus sunitinib for advanced gastrointestinal stromal tumor with KIT exon 11 + 17/18 mutations.
The INSIGHT study: a randomized, Phase III study of ripretinib versus sunitinib for advanced gastrointestinal stromal tumor with KIT exon 11 + 17/18 mutations.
Journal: Future oncology (London, England)
Published: September 04, 2024
Similar Doctors
Expertise in
8
conditions
Dr. Brian J. Druker
Hematology Oncology | Oncology
Expertise in
8
conditions
Dr. Brian J. Druker
Hematology Oncology | Oncology

University Professional Services

3181 Sw Sam Jackson Park Rd, 
Portland, OR 
 (0.7 mi)
503-494-8311
Experience:
44+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Brian Druker is a Hematologist Oncology specialist and an Oncologist in Portland, Oregon. Dr. Druker has been practicing medicine for over 44 years and is rated as an Elite provider by MediFind in the treatment of Chronic Myelogenous Leukemia (CML). His top areas of expertise are Chronic Myelogenous Leukemia (CML), Leukemia, Acute Myeloid Leukemia (AML), and Philadelphia-Negative Chronic Myeloid Leukemia. Dr. Druker is currently accepting new patients.

Expertise in
17
conditions
Dr. Gary W. Takahashi
Hematology Oncology
Expertise in
17
conditions
Dr. Gary W. Takahashi
Hematology Oncology
15700 Sw Greystone Court, 
Beaverton, OR 
 (8.2 mi)
503-203-1000
Languages Spoken:
English
See accepted insurances

Gary Takahashi is a Hematologist Oncology provider in Beaverton, Oregon. Dr. Takahashi and is rated as a Distinguished provider by MediFind in the treatment of Chronic Myelogenous Leukemia (CML). His top areas of expertise are Philadelphia-Negative Chronic Myeloid Leukemia, Chronic Myelogenous Leukemia (CML), Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET), and Myelodysplastic Syndrome (MDS).

Expertise in
16
conditions
Dr. Shane O. Rogosin
Oncology | Hematology
Expertise in
16
conditions
Dr. Shane O. Rogosin
Oncology | Hematology

Providence Health And Services Oregon

1500 Division St, Suite 220, 
Oregon City, OR 
 (10.6 mi)
503-513-1900
Experience:
21+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Shane Rogosin is an Oncologist and a Hematologist in Oregon City, Oregon. Dr. Rogosin has been practicing medicine for over 21 years and is rated as an Advanced provider by MediFind in the treatment of Chronic Myelogenous Leukemia (CML). His top areas of expertise are Lung Cancer, Small Cell Lung Cancer (SCLC), Pleuropulmonary Blastoma, Gallbladder Adenocarcinoma, and Bone Marrow Aspiration.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile